Metacrine, Inc.
Records under this name other than patents Metacrine, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,703,712 | Farnesoid X Receptor Agonists and Uses Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 11,214,538 | Farnesoid X Receptor Agonists and Uses Thereof Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 10,927,082 | Farnesoid X Receptor Agonists and Uses Thereof Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 10,961,198 | Farnesoid X Receptor Agonists and Uses Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 11,236,071 | Farnesoid X Receptor Agonists and Uses Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 11,084,817 | Farnesoid X Receptor Agonists and Uses Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 11,773,094 | Farnesoid X Receptor Agonists and Uses Thereof Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 12,491,160 | Formulations of a Farnesoid X Receptor Agonist Formerly held In force · High confidence | In force | High confidence | |
| US 8,623,845 | Pharmaceutical composition for preventing or treating Diabetes mellitus comprising bisphophonates Lapsed on the fee record Ended Jan 7, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jan 7, 2026 | From the USPTO record |
| US 10,626,081 | Farnesoid X receptor agonists and uses thereof Lapsed on the fee record Ended Apr 21, 2024 · From the USPTO record | Lapsed on the fee record | Ended Apr 21, 2024 | From the USPTO record |